Search research articles
Contact Us
Filters
Showing results (41-50 of 81) with videos related to
Page
of 9
Sort By:
Sarcoma
|
November 28, 2013
Rapid screening of novel agents for combination therapy in sarcomas
Christopher L Cubitt, Jiliana Menth, Jana Dawson, et al.
Cancer Research
|
October 7, 2020
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Joel G Turner, Yan Cui, Alexis A Bauer, et al.
Oncotarget
|
November 3, 2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G Turner, Trinayan Kashyap, Jana L Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
Adil I Daud, Jana Dawson, Ronald C DeConti, et al.
Leukemia Research
|
July 2, 2013
Sequence of novel agents in multiple myeloma: an instrumental variable analysis
Rachid Baz, Branko Miladinovic, Amila Patel, et al.
Molecular Cancer Therapeutics
|
August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
George R Simon, Richard M Lush, Jana Gump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias
Jeffrey E Lancet, Vu H Duong, Elliott F Winton, et al.
Investigational New Drugs
|
July 21, 2010
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
Christopher R Garrett, Domenico Coppola, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2008
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Adil I Daud, Ronald C DeConti, Stephanie Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors
Stacy L Moulder, John J Mahany, Richard Lush, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 81) with videos related to
Sort By:
Page
of 9
Sarcoma
|
November 28, 2013
Rapid screening of novel agents for combination therapy in sarcomas
Christopher L Cubitt, Jiliana Menth, Jana Dawson, et al.
Cancer Research
|
October 7, 2020
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma
Joel G Turner, Yan Cui, Alexis A Bauer, et al.
Oncotarget
|
November 3, 2016
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma
Joel G Turner, Trinayan Kashyap, Jana L Dawson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2009
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial
Adil I Daud, Jana Dawson, Ronald C DeConti, et al.
Leukemia Research
|
July 2, 2013
Sequence of novel agents in multiple myeloma: an instrumental variable analysis
Rachid Baz, Branko Miladinovic, Amila Patel, et al.
Molecular Cancer Therapeutics
|
August 25, 2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
George R Simon, Richard M Lush, Jana Gump, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 15, 2011
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias
Jeffrey E Lancet, Vu H Duong, Elliott F Winton, et al.
Investigational New Drugs
|
July 21, 2010
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
Christopher R Garrett, Domenico Coppola, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 26, 2008
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Adil I Daud, Ronald C DeConti, Stephanie Andrews, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2004
A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors
Stacy L Moulder, John J Mahany, Richard Lush, et al.
Page
of 9